HeimLONN • SWX
add
Lonza Group AG
Við síðustu lokun
567,00 CHF
Dagbil
570,00 CHF - 578,80 CHF
Árabil
467,80 CHF - 616,00 CHF
Markaðsvirði
41,44 ma. CHF
Meðalmagn
207,44 þ.
V/H-hlutf.
64,32
A/V-hlutfall
0,70%
Aðalkauphöll
SWX
Viðskiptafréttir
MarketWatch
fyrir 1 degi
Stock-market bulls are cheering a rare technical signal. Here’s how it works.
0,74%
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (CHF) | des. 2024info | Breyting á/á |
|---|---|---|
Tekjur | 1,76 ma. | -3,35% |
Rekstrarkostnaður | 317,50 m. | 20,27% |
Nettótekjur | 153,50 m. | 25,82% |
Hagnaðarhlutfall | 8,73 | 30,10% |
Hagnaður á hvern hlut | — | — |
EBITDA | 474,00 m. | -6,32% |
Virkt skatthlutfall | 14,48% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (CHF) | des. 2024info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 1,71 ma. | 2,52% |
Heildareignir | 19,73 ma. | 17,12% |
Heildarskuldir | 10,34 ma. | 41,02% |
Eigið fé alls | 9,39 ma. | — |
Útistandandi hlutabréf | 70,64 m. | — |
Eiginfjárgengi | 4,29 | — |
Arðsemi eigna | 4,18% | — |
Ávöxtun eigin fjár | 5,64% | — |
Peningaflæði
Breyting á handbæru fé
| (CHF) | des. 2024info | Breyting á/á |
|---|---|---|
Nettótekjur | 153,50 m. | 25,82% |
Handbært fé frá rekstri | 384,50 m. | -24,53% |
Reiðufé frá fjárfestingum | -930,50 m. | -181,97% |
Reiðufé frá fjármögnun | 404,50 m. | 239,00% |
Breyting á handbæru fé | -143,00 m. | -24,35% |
Frjálst peningaflæði | 199,06 m. | 115,93% |
Um
Lonza Group AG is a Swiss multinational manufacturing company for the pharmaceutical, biotechnology and nutrition sectors, headquartered in Basel, with major facilities in Europe, North America and South Asia. Lonza was established under that name in the late 19th-century in Switzerland. The company provides product development services to the pharmaceutical and biologic industries, including custom manufacturing of biopharmaceuticals and detection systems and services for the bioscience sector. Wikipedia
Stofnsett
1897
Höfuðstöðvar
Vefsvæði
Starfsfólk
18.470
